Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | F13A1 | P00488 | 1/20 | 0.53 |
| ▸ | FPR2 | P25090 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6966898 | 0.86 | CA2 (0.70) | CNR1RAB9ANPC1SMN1; SMN2EPHX1 | |
| SCHEMBL16857481 | 0.86 | CNR1 (0.73) | CNR1RAB9ANPC1SMN1; SMN2EPHX1 | |
| SCHEMBL19472639 | 0.85 | CNR1 (0.60) | CNR1RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL19472643 | 0.85 | CNR1 (0.76) | CNR1RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL19472655 | 0.85 | CNR1 (0.88) | CNR1RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL19472696 | 0.85 | CNR1 (0.76) | CNR1RAB9ANPC1SMN1; SMN2EPHX1 | |
| SCHEMBL19472678 | 0.84 | FPR2 (0.69) | CNR1RAB9ANPC1SMN1; SMN2EPHX1 | |
| SCHEMBL4657957 | 0.84 | CA2 (0.64) | CNR1RAB9ANPC1SMN1; SMN2EPHX1 | |
| SCHEMBL19472616 | 0.83 | KMT2A (0.60) | CNR1RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL19472646 | 0.82 | CNR1 (0.60) | CNR1RAB9ANPC1SMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183319-B2 | Phenylethylamine derivatives and their use in the treatment of melanoma | RILEY PATRICK ANTHONY | 2007-02-27 | — | — | US | disclosed |
| US-7183319-B2 | Phenylethylamine derivatives and their use in the treatment of melanoma | RILEY PATRICK ANTHONY | 2007-02-27 | — | — | US | disclosed |
| US-7183319-B2 | Phenylethylamine derivatives and their use in the treatment of melanoma | RILEY PATRICK ANTHONY | 2007-02-27 | — | — | US | disclosed |
| US-20040029967-A1 | Phenylethylamine derivatives and their use in the treatment of melanoma | RILEY PATRICK ANTHONY (GB) | 2004-02-12 | — | — | US | disclosed |
| EP-1303481-A1 | PHENYLETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MELANOMA | Riley, Patrick Anthony (GB) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002008174-A1 | PHENYLETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MELANOMA | RILEY PATRICK ANTHONY (GB) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029967-A1 | Phenylethylamine derivatives and their use in the treatment of melanoma | DOHH, DBH, HRH4 | CNR1 121/4885RAB9A 2052/4885NPC1 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.